This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): BIND014
Description: BIND-014 is docetaxel (Taxotere) encapsulated in a proprietary nanoparticle delivery system. The nanoparticles are coated with a targeting ligand (e.g. antibody or receptor ligand) designed to localize the drug payload to specific cellular sites.
The ligand on BIND-014 nanoparticles is targeted to prostate-specific membrane antigen (PSMA), a cell-surface antigen expressed on the surface of an array of solid tumors cells and the new blood vessels that feed them.
BIND-014 is being developed by BIND Biosciences. The development of BIND-014 was funded in part by the National Cancer Institute and the U.S. National Institutes of Standards and Technology (NIST) under its Advanced Technology Program (ATP).
BIND and Pfizer
In July 2016, BIND Therapeutics announced it has filed a motion for court approval of a stalking horse asset purchase agreement bid from Pfizer for the purchase of the majority of BIND's assets. The agreement is the initial stalking horse bid under Section 363 of the U.S. Bankruptcy Code, to be followed by an orderly auction process as established by the U.S. Bankruptcy Court. Under terms of the agreement, Pfizer has agreed to acquire substantially all of BIND's assets for approximately $20 million in cash subject to certain price adjustments. Pfizer has also agreed to assume certain contractual liabilities of BIND.
In August 2016, the acquisition closed, whereby BIND completed the sale of substantially...See full deal structure in Biomedtracker
Additional information available to subscribers only: